Norfolk、VAにおける乳がんの臨床試験
Norfolkとその周辺地域（約30マイル以内）の拠点で、乳がんに関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Sentara Norfolk General Hospital, Norfolk
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Virginia Oncology Associates, Norfolk
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Virginia Oncology Associates, Norfolk
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Sentara Norfolk General Hospital, Norfolk
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Virginia Oncology Associates, Norfolk
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
被験者募集中第1/2相
- Virginia Oncology Associates, Norfolk
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
被験者募集中第3相
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Norfolk
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Norfolk
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
被験者募集中第2相
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
被験者募集中第1/2相
- Virginia Cancer Institute, Norfolk
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Virginia Oncology Associates, Norfolk
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Virginia Oncology Associates, Norfolk
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
被験者募集中第2相
- Virginia Oncology Associates, Norfolk
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Norfolkにおける他の研究
- 膀胱癌8件の研究
- 前立腺がん8件の研究
- 腹部大動脈瘤7件の研究
- 卵巣がん7件の研究
- 非小細胞肺癌7件の研究
- がん（全種類）7件の研究
- 心不全7件の研究
- 心血管疾患7件の研究
- 脊髄性筋萎縮症6件の研究
- 末梢動脈疾患5件の研究
- トリプルネガティブ乳がん5件の研究
- 急性骨髄性白血病5件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。